Corcept Therapeutics Inc SEC Filings

Form 144 filed for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 20,000 common shares to be executed on 09/02/2025 through Stifel Nicolaus & Company, Inc. The shares were acquired the same day by stock option exercise and paid in cash. The filing lists total outstanding shares of 105,370,000 and an aggregate market value for the proposed sale of $1,394,400.00. The notice also discloses multiple sales by the same holder, William Guyer, during the prior three months, including a sale of 35,007 shares on 08/08/2025 for $2,512,452.00. The filer certifies there is no undisclosed material adverse information.

Form 144 filed for Corcept Therapeutics, Inc. (CORT) proposes the sale of 20,000 common shares through Stifel Nicolaus & Co. on 09/02/2025. The shares were acquired the same day via stock option exercise and payment was in cash. The filing identifies the seller as Sean Maduck, who reported multiple share sales in the prior three months totaling 60,000 shares and gross proceeds of $4,321,783.00. The proposed sale lists an aggregate market value of $1,394,400.00 and indicates the issuer's shares outstanding as 105,370,000. The notice includes the seller's attestation about absence of undisclosed material adverse information.

Corcept Therapeutics (CORT) Form 144 summary: This notice reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $348,600.00. The shares were acquired the same day, 09/02/2025, by stock option exercise and payment was in cash. The filing lists the issuer's total shares outstanding as 105,370,000 and indicates the intended exchange as NASDAQ. The filer previously sold several blocks of common stock in June–August 2025, totaling multiple transactions reported in the filing.

Corcept Therapeutics Inc. (CORT) filed a Form 144 notifying a proposed Rule 144 sale of 40,000 common shares through Stifel Nicolaus & Company Inc., with an aggregate market value of $2,788,800 and an approximate sale date of 09/02/2025. The filing reports the shares were acquired on 07/06/2022 by stock option exercise and paid for in cash. The filing also discloses recent sales by the same named seller, Joseph Belanoff: 40,000 shares on 06/02/2025 for $3,314,310, 615 shares on 07/17/2025 for $45,318, and 40,000 shares on 08/04/2025 for $2,742,006. The issuer’s total shares outstanding are listed as 105,370,000. The notice includes the seller’s representation that he has no undisclosed material adverse information.

Corcept Therapeutics (CORT) Chief Business Officer Gary Charles Robb reported multiple transactions on 08/22/2025. He acquired 5,000 stock options with a $3.88 exercise price that are fully exercisable and result in 5,000 underlying shares upon exercise. On the same date he sold 2,326 shares at $71.27 and had 2,674 shares withheld at ~$71.17 to satisfy exercise price and taxes from a net exercise. Following these transactions Robb directly beneficially owns 13,364 common shares and indirectly holds 11,571 shares in custodial accounts for his children. The filing notes 2,082 unvested restricted shares (grants from 2024–2025) that vest one year after each grant date if conditions are met.

Form 144 for Corcept Therapeutics (CORT) shows a proposed sale of 2,326 common shares acquired by stock option exercise on 08/22/2025, with cash payment the same day. The sale is through Fidelity Brokerage Services LLC on NASDAQ and the reported aggregate market value is $165,774.02. The filing also lists a prior sale on 06/16/2025 of 3,185 shares generating $225,402.45. The issuer’s outstanding shares are reported as 105,371,729. The filer certifies no undisclosed material adverse information is known.

On 08/11/2025, Daniel N. Swisher Jr., a director of Corcept Therapeutics (CORT), exercised stock options and sold the resulting shares under a pre-established plan. He exercised options with a $14.08 exercise price to acquire 2,200 common shares and sold 2,200 shares at $72.30, leaving him with 0 direct common shares following the transactions. The trades were executed pursuant to a 10b5-1 plan adopted August 1, 2024. After the transactions he retains beneficial ownership of 5,500 stock options that are reported as fully exercisable.

William Guyer, Chief Development Officer of Corcept Therapeutics (CORT) reported insider transactions dated 08/08/2025. The Form 4 shows derivative and non-derivative activity executed pursuant to a 10b5-1 plan adopted on 11/27/2024. The filing reports acquisition in Table II of a stock option granting the right to buy 35,007 shares with an exercise price of $21.65; that option is shown as fully exercisable and carries an expiration date of 09/01/2031. Table II lists 350,000 derivative securities beneficially owned following the reported transaction.

Table I records non-derivative movements on the same date, including a reported disposition coded S of 35,007 common shares at a price of $71.77. The two Table I lines display reported beneficial ownership amounts of 40,494 and 5,487 shares respectively after the reported transactions. The Form notes the 10b5-1 plan governed the transactions.

Corcept Therapeutics (CORT) filed a Form 144 reporting an intended sale of 2,200 common shares through Fidelity on NASDAQ with an aggregate market value of $159,060. The filing lists total shares outstanding of 105,371,729, showing the proposed block represents a very small fraction of outstanding stock.

The securities are shown as acquired in connection with an option granted 08/20/2018 and the filing indicates acquisition and proposed sale activity on 08/11/2025 for cash. The filer, Daniel Swisher, also reported three prior sales in the past three months (2,200 shares each on 05/12/2025, 06/10/2025 and 07/10/2025) with listed gross proceeds for each sale.